Pharmacokinetics and Safety of Letermovir and Midazolam Coadministration in Healthy Subjects

• Published in: Clinical pharmacology in drug development Vol. 11; no. 1; pp. 16 - 24
• Main Authors: Kropeit, Dirk, McCormick, David, Erb‐Zohar, Katharina, Stobernack, Hans‐Peter, Zimmermann, Holger, Rübsamen‐Schaeff, Helga
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.01.2022
• Subjects: Acetates; Antiviral drugs; Area Under Curve; Cytomegalovirus; Drug Interactions; Female; Healthy Volunteers; human cytomegalovirus; Humans; letermovir; midazolam; Midazolam - administration & dosage; Midazolam - adverse effects; Midazolam - pharmacokinetics; Pharmacokinetics; Quinazolines; Stem cell transplantation; terminase inhibitor; letermovir; drug interactions; terminase inhibitor; midazolam; human cytomegalovirus

Letermovir is a human cytomegalovirus (CMV) terminase inhibitor for the prophylaxis of CMV infection and disease in allogeneic hematopoietic stem‐cell transplant recipients. In vitro studies have identified letermovir as a potential cytochrome P450 (CYP) 3A inhibitor. Thus, the effect of letermovir...